- Home
- TNGX vs ARCT Comparison
TNGX vs ARCT Comparison
Compare TNGX & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNGX
- ARCT
- Stock Information
- Founded
- TNGX 2014
- ARCT 2013
- Country
- TNGX United States
- ARCT United States
- Employees
- TNGX N/A
- ARCT N/A
- Industry
- TNGX Biotechnology: Pharmaceutical Preparations
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- TNGX Health Care
- ARCT Health Care
- Exchange
- TNGX Nasdaq
- ARCT Nasdaq
- Market Cap
- TNGX 413.6M
- ARCT 602.7M
- IPO Year
- TNGX N/A
- ARCT N/A
- Fundamental
- Price
- TNGX $3.13
- ARCT $17.07
- Analyst Decision
- TNGX Strong Buy
- ARCT Strong Buy
- Analyst Count
- TNGX 8
- ARCT 7
- Target Price
- TNGX $13.14
- ARCT $65.00
- AVG Volume (30 Days)
- TNGX 1.4M
- ARCT 377.4K
- Earning Date
- TNGX 11-06-2024
- ARCT 11-07-2024
- Dividend Yield
- TNGX N/A
- ARCT N/A
- EPS Growth
- TNGX N/A
- ARCT N/A
- EPS
- TNGX N/A
- ARCT N/A
- Revenue
- TNGX $43,383,000.00
- ARCT $160,399,000.00
- Revenue This Year
- TNGX $27.73
- ARCT $7.33
- Revenue Next Year
- TNGX N/A
- ARCT $4.71
- P/E Ratio
- TNGX N/A
- ARCT N/A
- Revenue Growth
- TNGX 15.67
- ARCT N/A
- 52 Week Low
- TNGX $2.70
- ARCT $14.30
- 52 Week High
- TNGX $13.01
- ARCT $45.00
- Technical
- Relative Strength Index (RSI)
- TNGX 42.05
- ARCT 49.65
- Support Level
- TNGX $2.95
- ARCT $16.01
- Resistance Level
- TNGX $3.20
- ARCT $17.25
- Average True Range (ATR)
- TNGX 0.27
- ARCT 1.15
- MACD
- TNGX 0.08
- ARCT 0.15
- Stochastic Oscillator
- TNGX 72.88
- ARCT 71.58
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in the research and development segment of medical applications for nucleic acid-focused technology. The company's product pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU and LUNAR-COV19.